• Cell Source posted a net loss of about USD 1.48 million for the three months ended March 31, 2025, while generating no revenue.
• Research and development expense rose 45% to USD 515,183, primarily due to additional expenses tied to new amendments with MD Anderson.
• General and administrative expense fell 38% to USD 483,404, reflecting lower consulting, stock-based compensation, and external services costs.
• Interest expense more than doubled to USD 427,237, while amortization of debt discount increased to USD 86,637.
• Cash dropped to USD 1,240 at March 31, 2025, with working capital deficiency widening to about USD 20.14 million; MD Anderson Phase 1/2 trial using anti-viral Veto Cells completed five cohorts with 15 patients, showing no toxicity and no severe GvHD.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cell Source Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-022926), on May 14, 2026, and is solely responsible for the information contained therein.